Biohaven
252 articles about Biohaven
-
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - April 22, 2024
4/22/2024
Biohaven Ltd. announced the closing of its underwritten public offering of 6,451,220 of its common shares, which includes the full exercise of the underwriters' option to purchase 841,463 additional common shares, at a public offering price of $41.00 per share.
-
Biohaven Announces Pricing of $230 Million Public Offering of Common Shares
4/18/2024
Biohaven Ltd. announced the pricing of its underwritten public offering of 5,609,757 of its common shares at a price to the public of $41.00 per share.
-
Biohaven Announces Proposed Public Offering of Common Shares - April 17, 2024
4/17/2024
Biohaven Ltd. announced that it has commenced an underwritten public offering of $200 million of its common shares.
-
Biohaven Showcases Innovative Neuroscience Portfolio with 20 Presentations at the 2024 American Academy of Neurology (AAN) Annual Meeting and Provides Other Business Updates
4/13/2024
Biohaven Ltd. announced that 20 abstracts, including 8 oral presentations and 12 posters, will be featured this weekend starting April 13th at the 2024 American Academy of Neurology Annual Meeting, taking place in Denver, Colorado.
-
Biohaven Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Developments
2/29/2024
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a review of recent accomplishments and anticipated upcoming developments.
-
Biohaven to Present at the 42nd Annual J.P. Morgan Healthcare Conference
1/2/2024
Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 42nd Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Monday, January 8, 2024 at 8:15 am (PT).
-
Biohaven Reports Third Quarter 2023 Financial Results and Recent Business Developments
11/14/2023
Biohaven Ltd. reported financial results for the third quarter ended September 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
-
Biohaven Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares - October 6, 2023
10/5/2023
Biohaven Ltd. today announced the closing of its underwritten public offering of 11,761,363 of its common shares, which includes the full exercise of the underwriters' option to purchase 1,534,090 additional common shares, at a public offering price of $22.00 per share.
-
Biohaven Announces Pricing of $225 Million Public Offering of Common Shares
10/3/2023
Biohaven Ltd. announced the pricing of its underwritten public offering of 10,227,273 of its common shares at a price to the public of $22.00 per share.
-
Biohaven Announces Proposed Public Offering of Common Shares - October 02, 2023
10/2/2023
Biohaven Ltd., a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, announced that it has commenced an underwritten public offering of $200 million of its common shares.
-
Biohaven Announces Positive Data from its Exploratory Electroencephalogram (EEG) Biomarker Study of BHV-7000, Completion of Once-Daily Formulation Development, and Plan to Initiate Phase 3 Pivotal Studies
9/5/2023
Biohaven Ltd. announced preliminary analyses and positive biomarker data from Biohaven's exploratory Phase 1 electroencephalogram biomarker study, which was presented to epilepsy key opinion leaders at an off-site meeting held during the International Epilepsy Conference 2023 in Dublin, Ireland.
-
With a potential $509 billion up for grabs by 2028, companies including Biogen, Sage, Karuna Therapeutics and Cerevel Therapeutics are vying to bring their drugs across the regulatory finish line.
-
Biohaven's Taldefgrobep Alfa Receives EU Orphan Drug Designation for Spinal Muscular Atrophy
7/31/2023
Biohaven Ltd. (NYSE: BHVN; "Biohaven") announced today that it received orphan medicinal product designation from the European Commission (EC) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA).
-
Biohaven Reports Second Quarter 2023 Financial Results and Recent Business Developments
7/31/2023
Biohaven Ltd. (NYSE: BHVN) (Biohaven or the Company), a global clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of life-changing therapies to treat a broad range of rare and common diseases, today reported financial results for the second quarter ended June 30, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
-
Biohaven Provides Overview of Clinical Progress, Regulatory Updates, and Pipeline Developments at R&D Day
5/31/2023
Biohaven Ltd. will provide an overview of clinical progress, regulatory updates, and pipeline developments at an in-person R&D Day , concurrently with the Yale Ventures' Innovation Summit 2023 taking place on May 31-June 1.
-
Biohaven Reports First Quarter 2023 Financial Results and Reports Recent Business Developments
5/12/2023
Biohaven Ltd. reported financial results for the first quarter ended March 31, 2023, and provided a review of recent accomplishments and anticipated upcoming milestones.
-
Biohaven Expands Executive Leadership Team with Appointment of Nick Kozauer M.D. as Senior Vice President for Clinical Development and Regulatory Strategy
4/17/2023
Biohaven Ltd., a global clinical-stage biopharmaceutical company, announced that Nick Kozauer, M.D. has joined its executive leadership team as Senior Vice President for Clinical Development and Regulatory Strategy.
-
Biohaven's Taldefgrobep Alfa Receives FDA Fast Track Designation for Spinal Muscular Atrophy
2/21/2023
Biohaven Ltd. (NYSE: BHVN; "Biohaven") announced today that it received Fast Track designation from the U.S. Food and Drug Administration (FDA) for taldefgrobep alfa, a novel anti-myostatin adnectin, for the treatment of spinal muscular atrophy (SMA).
-
Biohaven to Present at the 41st Annual J.P. Morgan Healthcare Conference
1/6/2023
Biohaven Ltd. (NYSE: BHVN) today announced that Vlad Coric, M.D., Chairman and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference at The Westin St. Francis Hotel in San Francisco, California, on Tuesday, January 10, 2023 at 7:30 am (PT).
-
Biohaven Advances Development of the MoDE Platform Technology Licensed From Yale University
10/25/2022
Biohaven Ltd. announced advancements in the development of its MoDE extracellular target degrader platform technology licensed from Yale University for various disease indications, including, but not limited to, neurological disorders, cancer, infectious and autoimmune diseases.